DBS Imaging-based vs. Threshold Assessment-based Programming
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jan 23, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to program a treatment called deep brain stimulation (DBS) for people with Parkinson's disease. The main goal is to see if using brain imaging to guide the DBS programming can help reduce motor symptoms just as effectively as a method that measures patients' responses to specific movements. Participants in the study will either receive the imaging-based programming or the threshold assessment-based programming, and their progress will be monitored over six months.
To join the trial, participants must be at least 18 years old and have a diagnosis of Parkinson's disease. They should also be scheduled for DBS screening and understand the Dutch language. However, people with certain conditions, like dementia or severe mental health issues, or those who have had previous brain surgeries, won't be eligible. Throughout the study, participants can expect careful monitoring of their motor symptoms, physical abilities, and overall quality of life to see how effective each programming method is.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parkinson's disease diagnosis based on the clinical diagnostic criteria of Movement Disorder Society
- • Scheduled for DBS screening
- • Age of 18 years or older
- • Understand the Dutch language
- Exclusion Criteria:
- • Legally incompetent adults
- • No written informed consent
- • Previous functional stereotactic neurosurgery
- • Dementia
- • Current depression or psychosis
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, North Holland, Netherlands
Patients applied
Trial Officials
Rob de Bie, Prof
Principal Investigator
Amsterdam UMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported